US gambles $24.9m to speed Ebola drug ZMapp
This article was originally published in Scrip
Executive Summary
Gambling big that positive animal study results will translate into human efficacy, the US Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), put $24.9m on the table to support an 18-month contract with Mapp Biopharmaceutical to help speed the development of its experimental Ebola drug ZMapp.